Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FRLN

Freeline Therapeutics (FRLN) Stock Price, News & Analysis

Freeline Therapeutics logo

About Freeline Therapeutics Stock (NASDAQ:FRLN)

Advanced Chart

Key Stats

Today's Range
$6.48
$6.48
50-Day Range
$6.43
$6.49
52-Week Range
$2.11
$8.74
Volume
N/A
Average Volume
12,055 shs
Market Capitalization
$28.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive FRLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FRLN Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
Acquisition of Freeline by Syncona Becomes Effective
Acquisition of Freeline by Syncona Becomes Effective
Freeline Therapeutics Shareholders Approve Acquisition by Syncona
Freeline Shareholders Approve Acquisition by Syncona
Freeline Therapeutics Holdings plc (FRLN)
See More Headlines

FRLN Stock Analysis - Frequently Asked Questions

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($12.90) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($15.20) by $2.30.

Freeline Therapeutics's stock reverse split before market open on Friday, May 12th 2023.The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Freeline Therapeutics (FRLN) raised $126 million in an initial public offering on Friday, August 7th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Freeline Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Jabil (JBL), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
11/09/2021
Today
7/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:FRLN
Fax
N/A
Employees
152
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.97 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$12.07 per share
Price / Book
0.54

Miscellaneous

Free Float
4,259,000
Market Cap
$28.12 million
Optionable
Not Optionable
Beta
0.66
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:FRLN) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners